Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trichoplein keratin filament-binding protein (TCHP) is a cytoskeletal-associated protein discovered as a binder of keratins 8/18, prominent intermediate filament proteins in epithelial cells[1]. It interacts directly with several keratins (K8, K18, K16, to a lesser extent K5, K6a, K14), and colocalizes with desmosomes and keratin filaments, mainly at apical regions of simple epithelial cells[1][5]. TCHP acts as a tumor suppressor by inhibiting cell growth and promoting apoptosis, in part via down-regulation of HSPB1 phosphorylation in cancer cells[2][5]. It also functions as a negative regulator of ciliogenesis and may act as a capping or branching protein for keratin filaments, helping maintain epithelial cell structure and integrity[5]. Mutations or dysregulation can contribute to cancer development[2]. There are no current drugs targeting TCHP, and its main research importance lies in understanding cytoskeletal regulation and cancer biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trichoplein keratin filament-binding protein (TCHP).